Live
FierceBiotechBeyond the Hype: Turning NAMs into Actionable EvidenceFierceBiotechRevolution’s much-hyped RAS inhibitor hits key survival goals in phase 3 pancreatic cancer trialFierceBiotechAbbVie inks $745M deal with Chinese biotech Haisco for two acute pain assetsFierceBiotechSpyre points to phase 2 win for ulcerative colitis drug as proof it could take on Takeda’s EntyvioBioPharma DiveRevolution pancreatic cancer drug nearly doubles survival in key trialThermo FisherThermo Fisher Scientific’s PPD Clinical Research Business Collaborates with HealthVerity to Expand R - PharmiWeb.comEndpoints NewsAllogene’s first cut of data on ‘off-the-shelf’ CAR-T shows promiseEndpoints NewsNeomorph raises $100M for molecular glues; Spyre's ulcerative colitis dataBioWorldBiggest gainers and losers for April 6-10, 2026Endpoints NewsRegeneron wades into radiopharma through $40M upfront deal with TelixEndpoints NewsBioNTech's HER2 ADC succeeds in Phase 2 study, FDA filing plannedThermo FisherSmall Molecule Innovator API CDMO Market Outlook, 2026-2033 - Lonza Group, Novo Holdings (Catalent) and Thermo Fisher Scientific Lead the Growing Industry - Yahoo Finance UK
FierceBiotech Apr 13, 2026

Revolution’s much-hyped RAS inhibitor hits key survival goals in phase 3 pancreatic cancer trial

Revolution’s much-hyped RAS inhibitor hits key survival goals in phase 3 pancreatic cancer trial

Original
Body unavailable. Use the original source.

Directory

59 All